Generics in Canada: The race for market exclusivity

The Supreme Court of Canada has tentatively set April 20, 2015 as the date for the hearing of Sanofi’s appeal against a court’s decision that the company is liable for generic drug maker Apotex’s lost sales of ramipril based on section 8 of the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Abbott IP chief: ‘Firms without AI policies scare me’

5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.

Americas

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.

Americas

To cite or not to cite: How can we avoid misuse of AI in court?

4 March 2026 With an increase in ‘hallucinated’ case law cited as evidence in courts globally, what can legal practitioners—as well as providers of AI tools and platforms—do to help safeguard against this? Sarah Speight finds out.

More features

Abbott IP chief: ‘Firms without AI policies scare me’

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

FisherBroyles opens San Diego office

To cite or not to cite: How can we avoid misuse of AI in court?

Emotional Perception: What next for patent holders?

LSPN Awards 2026 finalists revealed

Natera and a rival draw the line under five-year fight

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Generics in Canada: The race for market exclusivity

More on this story

Editor's picks

Editor's picks

More features